Navigation Links
Reportlinker Adds Actelion Ltd: PharmaVitae Profile
Date:9/23/2010

NEW YORK, Sept. 23 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Actelion Ltd: PharmaVitae Profile

http://www.reportlinker.com/p0186216/Actelion-Ltd-PharmaVitae-Profile.html

Introduction

This analysis examines the historical and forecast performance for Actelion in the Rx pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Scope

Highlights

Reasons to Purchase

-  Benchmark Actelion's performance against key rivals in the ethical pharmaceutical sector

-  Learn how Actelion's focus on a novel pathophysiological pathway has rapidly transformed it from a startup biotech into a billion dollar company

-  Evaluate the impressive pipeline potential that is set to drive Actelion's future commercial focus

ABOUT DATAMONITOR HEALTHCARE 2

About the PharmaVitae team 2

Chapter 1 About this profile 3

PharmaVitae Explorer database 3

Chapter structure 3

Executive summary 3

Quarterly update 3

Company introduction 3

Company sales 4

Company financials 4

Key products 4

Data sourcing 4

Sales data 4

Analyst consensus 4

Chapter 2 Executive summary 5

Key findings 5

Prescription pharmaceutical sales and growth rate performance, 2003-15 6

Financial performance, 2003-15 7

Actelion: PharmaVitae forecasts at a glance 8

Strategic insight 9

Rapid evolution of a successful biotech company 9

Extensive clinical development program can breathe new life into Tracleer 11

Novel CNS drug almorexant offers significant growth potential beyond Actelion's existing specialist disease focus 11

Innovative pipeline efforts draws Big Pharma attention 12

SWOT analysis 14

Table of Contents 15

Table of figures 17

Chapter 3 Quarterly news update 18

Latest prescription pharma product news 18

Q1 2010 18

Q4 2009 18

Q3 2009 19

Q2 2009 19

Q1 2009 20

Latest corporate news 20

Q4 2009 20

Q3 2009 20

Q2 2009 20

Q1 2009 20

Future product milestones 21

Chapter 4 Company introduction 22

Key findings 22

Background 23

Key corporate developments 23

M&A history 24

Axovan 24

CoTherix 24

Chapter 5 Company sales 26

Key findings 26

Prescription pharmaceutical sales and growth rate analysis, 2003-15 27

Product analysis 28

Product analysis, 2003-09 29

Product analysis, 2009-15 30

Therapy area analysis 32

Geographic analysis 33

Launch/core/expiry analysis 34

Explanation of launch/core/expiry analysis 34

Launch analysis, 2009-15 35

Core analysis, 2009-15 36

Expiry analysis, 2009-15 37

Launch/core/expiry configuration, 2009-15 38

Molecule type analysis 39

Externalization analysis 40

Chapter 6 Company financials 41

Key findings 41

Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2003-09 42

Operating costs and profit analysis 43

Operating costs and profit analysis, 2003-09 44

Operating cost ratio and profit margin analysis, 2003-09 44

Operating cost ratio and profit margin analysis, 2009-15 45

Operating costs and profit analysis, 2009-15 45

Chapter 7 Key products 46

Overview 46

Tracleer 47

Summary 48

Sales forecast 49

Amorexant 50

Summary 51

Sales forecast 52

Macitentan 53

Summary 54

Sales forecast 55

Epoprostenol 56

Summary 57

Sales forecast 58

Clazosentan 60

Summary 61

Sales forecast 62

Zavesca 63

Summary 64

Sales forecast 65

Ventavis 67

Summary 68

Sales forecast 69

Chapter 8 Appendix 70

References 70

Abbreviations 70

Exchange rates 71

About Datamonitor 72

About Datamonitor Healthcare 72

Datamonitor consulting 72

Disclaimer 74

List of Tables Table 1: Actelion - PharmaVitae forecasts at a glance 8

Table 2: Efficacy and safety comparison of ERA therapies 11

Table 3: Actelion future product milestones, 2010-12 21

Table 4: Actelion product portfolio overview ($m), 2003-09 29

Table 5: Actelion product portfolio overview ($m), 2009-15 30

Table 6: Actelion launch portfolio overview ($m), 2009-15 35

Table 7: Actelion core portfolio overview ($m), 2009-15 36

Table 8: Actelion expiry portfolio overview ($m), 2009-15 37

Table 9: Total Actelion sales by business unit ($m), 2003-09 42

Table 10: Actelion operating revenue/cost analysis ($m), 2003-09 44

Table 11: Actelion operating cost ratio analysis (% of total revenues), 2003-09 44

Table 12: Actelion operating cost ratio analysis (% of total revenues), 2009-15 45

Table 13: Actelion operating revenue/cost analysis ($m), 2009-15 45

Table 14: Actelion Key products overview 46

Table 15: Tracleer: overview 48

Table 16: Tracleer: sales forecast ($m), 2009-15 49

Table 17: Almorexant: overview 51

Table 18: Almorexant: sales forecast ($m), 2009-15 52

Table 19: macitentan: overview 54

Table 20: macitentan: sales forecast ($m), 2009-15 55

Table 21: epoprostenol: overview 57

Table 22: epoprostenol: sales forecast ($m), 2009-15 58

Table 23: clazosentan: overview 61

Table 24: epoprostenol: sales forecast ($m), 2009-15 62

Table 25: Zavesca: overview 64

Table 26: Zavesca: sales forecast ($m), 2009-15 65

Table 27: Ventavis: overview 68

Table 28: Ventavis: sales forecast ($m), 2009-15 69

Table 29: Exchange rates, 2010 71

List of Figures Figure 1: The PharmaVitae Explorer 3

Figure 2: Actelion prescription pharmaceutical performance, sales ($m) and growth rate (%), 2003-15 6

Figure 3: Actelion's financial performance ($m), 2003-15 7

Figure 4: Startup financing cycle 9

Figure 5: Actelion SWOT analysis 14

Figure 6: Actelion prescription pharmaceutical performance, sales ($m) and growth rate (%), 2003-15 27

Figure 7: Actelion Key product sales ($m), 2003-15 28

Figure 8: Actelion key sales growth drivers and resistors ($m), 2003-09 29

Figure 9: Actelion key sales growth drivers and resistors ($m), 2009-15 31

Figure 10: Actelion prescription pharmaceutical sales by therapy area ($m), 2003-15 32

Figure 11: Actelion prescription pharmaceutical sales by geographic region ($m), 2003-15 33

Figure 12: Actelion launch/core/expiry configuration ($m), 2009-15 38

Figure 13: Actelion prescription pharmaceutical sales by molecule type ($m), 2003-15 39

Figure 14: Actelion prescription pharmaceutical sales by source ($m), 2003-15 40

Figure 15: Actelion operating revenue/cost analysis ($m), 2003-15 43

To order this report:Pharmaceutical Industry: Actelion Ltd: PharmaVitae Profile

Pharmaceutical Business News

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!Contact Nicolas BombourgReportlinkerEmail: nbo@reportlinker.comUS: (805)652-2626Intl: +1 805-652-2626
'/>"/>

SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Reportlinker Adds US Disposable Medical Supplies Market Report
2. Reportlinker Adds Gilead Sciences Inc.: PharmaVitae Profile
3. Reportlinker Adds Drug Delivery Partnering Agreements in Pharma and Biotech
4. Reportlinker Adds Global Medical Devices Industry Outlook to 2010: Marketing And Sales Strategies And The Impact of Recession And Recovery
5. Reportlinker Adds Reinventing Pharmaceutical Sales Forces
6. Reportlinker Adds Computer Assisted Coding Of Medical Information Market Shares, Strategies, and Forecasts 2008 to 2014
7. Reportlinker Adds Global Drug Manufacturing Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery
8. Reportlinker Adds Global Anesthesia and Respiratory Devices Market Analysis and Forecasts to 2015
9. Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014: Policy environment, market structure, competitive landscape, growth opportunities
10. Reportlinker Adds Global Top 10 Chemical Companies -- Industry, Financial and SWOT Analysis
11. Reportlinker Adds Pharma 101: An Overview of the Life Sciences Industry (Analyst Insight)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... -- Research and Markets has announced the addition ... to their offering. The ... commercial environment for MedImmune to enter. The US ageing population ... to drive considerable growth for effective anti-influenza medications. The introduction ... considerably, but development is still in its infancy. ...
(Date:6/23/2016)... and INDIANAPOLIS , June 23, ... a Lilly Diabetes Tomorrow,s Leaders Scholarship is any indication, ... winners, announced today online at www.diabetesscholars.org by ... 1 diabetes stand in the way of academic and ... the Foundation,s scholarship program since 2012, and continues to ...
(Date:6/23/2016)... , June 23, 2016  Guerbet announced today that ... Supplier Horizon Award . One of ... was recognized for its support of Premier members through ... clinical excellence, and commitment to lower costs. ... this recognition of our outstanding customer service from Premier," ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, A Forever Recovery, ... Festival and World’s Longest Breakfast Table in Battle Creek, MI, where the rehabilitation facility ... home to some of the world’s leading providers of cereal and other breakfast foods. ...
(Date:6/25/2016)... ... 25, 2016 , ... Experts from the American Institutes for ... Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. , AIR ... care planning, healthcare costs and patient and family engagement. , AIR researchers will ...
(Date:6/25/2016)... Beach, CA (PRWEB) , ... June 25, 2016 , ... ... UCLA with Magna Cum Laude and his M.D from the David Geffen School of ... Diego and returned to Los Angeles to complete his fellowship in hematology/oncology at the ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events ... turn to unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. ... tools for healthy coping following a traumatic event. , Trauma sufferers tend to feel ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. ... accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas of orthodontics, ... and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic ...
Breaking Medicine News(10 mins):